Download
Download by
Scanning QR Code
  • Download app

    Download app

  • Online Inquiry

    Log in to access Online Inquiry
+
Congratulations
You've successfully got advanced quotes worth 5000 HKD
Download APP >>
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
GLMD Galmed Pharmaceuticals
0.419
-0.010-2.28%
YOY
Do not show
Hide blank lines
(Q2)2022/06/30(Q1)2022/03/31(FY)2021/12/31(Q4)2021/12/31
Total revenue
0 0 0 0
Operating revenue
-- 0 -- 0 -- 0 -- 0
Cost of revenue
Gross profit
Operating expense
-55.66% 3.73M -33.29% 6.09M 8.84% 32.88M -27.56% 7.49M
Selling and administrative expenses
-16.42% 1.15M -26.03% 1.3M 37.14% 5.66M -6.68% 1.23M
-General and administrative expense
-16.42% 1.15M -26.03% 1.3M 37.14% 5.66M -6.68% 1.23M
Research and development costs
-63.33% 2.58M -35.01% 4.8M 4.36% 27.22M -30.6% 6.26M
Operating profit
55.66% -3.73M 33.29% -6.09M -8.84% -32.88M 27.56% -7.49M
Net non-operating interest income expense
-125% -4K -122.47% -51K -55.3% 519K -38.46% 40K
Non-operating interest income
-- -- -- -- -52.85% 562K -- --
Total other finance cost
-- 4K -- 51K 38.71% 43K -- --
Other net income (expense)
-137.77% -105K
Gain on sale of security
-- -- -- -- -137.77% -105K -- --
Income before tax
55.53% -3.73M 31.02% -6.14M -12.85% -32.47M 27.49% -7.45M
Income tax
Net income
55.53% -3.73M 31.02% -6.14M -12.85% -32.47M 27.49% -7.45M
Net income continuous Operations
55.53% -3.73M 31.02% -6.14M -12.85% -32.47M 27.49% -7.45M
Minority interest income
Net income attributable to the parent company
55.53% -3.73M 31.02% -6.14M -12.85% -32.47M 27.49% -7.45M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders
55.53% -3.73M 31.02% -6.14M -12.85% -32.47M 27.49% -7.45M
Basic earnings per share
54.55% -0.15 36.84% -0.24 2.22% -1.32 37.5% -0.3
Diluted earnings per share
54.55% -0.15 36.84% -0.24 2.22% -1.32 37.5% -0.3
Dividend per share
Currency Unit
USDUSDUSDUSD
Accounting Standards
US-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions
----Unqualified Opinion--

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a research agreement with Gannex Pharma Co., Ltd. to develop a combination therapy of ASC41 (THR-beta agonist) and Aramchol (SCD 1 inhibitor) for the treatment of NASH; a research and development collaboration agreement with MyBiotics Pharma Ltd. to identify the selected microbiome repertoire associated with the response to Aramchol; and a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.
CEO: Baharaff, Allen
Market: NASDAQ
Futu Hot List
USHKCN
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist
Back to the Top